Checkmate Pharmaceuticals Stock Price, News & Analysis
Company Description
Checkmate Pharmaceuticals (NASDAQ: CMPI) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $231.4M.
CMPI stock has gained 57.2% over the past year.
This page provides a comprehensive overview of CMPI stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Checkmate Pharmaceuticals (CMPI) stock. Over the past 12 months, the stock has gained 57.2%. At a market capitalization of $231.4M, CMPI is classified as a micro-cap stock with approximately 22.0M shares outstanding.
Latest News
Checkmate Pharmaceuticals has 10 recent news articles. Of the recent coverage, 9 articles coincided with positive price movement and 1 with negative movement. Key topics include clinical trial, earnings, acquisition, conferences, management. View all CMPI news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
CMPI Company Profile & Sector Positioning
Checkmate Pharmaceuticals (CMPI) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing CMPI often look at related companies in the same sector, including Voyager Therapeutics Inc (VYGR), Third Harmonic Bio Inc (THRD), AC Immune (ACIU), Humacyte Inc (HUMA), and Proqr Therapeuti (PRQR). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CMPI's relative position within its industry.